UST and MRK showed a positive trend toward maintaining clinical response; however, the 95% CIs were wide and crossed the null value, indicating limited certainty of evidence ( Table 3 ). 200 mg GUS (RR: 3.34, 95% CI: 1.95–5.72, SUCRA = 96.8) and 100 mg GUS (RR: 3.05, 95% CI: 1.77–5.25, SUCRA = 83.2) ranked first and second, respectively ( Figure 6 b).
← all excerpts
Comparing the Efficacy of Advanced Interleukin Inhibitors for Crohn's Disease: A Systematic Review and Network Meta-Analysis.
1
—
—